{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:04:00Z","timestamp":1789977840928,"version":"4.0.1"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MC"],"published-print":{"date-parts":[[2026,9,16]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Pyrazinones remain a comparatively underexplored class of nitrogen heterocycles,\ndespite their recurrence in bioactive natural products and their emergence as a privileged scaffold\nengaging viral polymerases, kinases, proteases, and G-protein-coupled receptors. Unlike\nprior reviews, typically confined to a single therapeutic class or to synthetic methodology alone,\nthis review is the first to integrate the natural occurrence, synthetic access, structure-activity relationships,\nand clinical translatability of pyrazinone derivatives within a single framework, and\nin doing so identifies structural determinants that recur across nine otherwise unrelated therapeutic\nareas rather than being specific to any one target. Three such determinants emerge consistently:\nhalogenation at C-3\/C-5 improves potency and metabolic stability across kinase, protease,\nand antifungal series alike; hydrogen-bond donor\/acceptor substituents are well tolerated\nat N-1\/C-6 but sharply disruptive when placed adjacent to the lactam at N-3\/C-2, reflecting a\nconserved role for this region in target recognition; and lipophilic extensions at N-1\/C-6 raise\ncellular potency at the recurring cost of selectivity. Inherent limitations are critically examined,\nincluding lactam-lactim tautomeric equilibria, challenges in regioselective functionalization,\nand the trade-off between aqueous solubility and membrane permeability, alongside ADMET\nconsiderations such as metabolic stability and off-target toxicity. A central finding of this synthesis\nis that, across almost every therapeutic class surveyed, reported activity data remain confined\nto in vitro measurements, without matching pharmacokinetic or translatability data, indicating\nthat the principal bottleneck to clinical progression is evaluative rather than a shortage of\npotent chemical matter. Clinically relevant examples, including the antiviral drug favipiravir\nand the clinical-stage candidates RWJ-671818 and BI 730357, nonetheless demonstrate that this\nbottleneck is surmountable and illustrate the scaffold's translational potential. Recent advances,\nemerging resistance mechanisms, and future directions, including multi-target-directed ligand\ndesign, structure-based optimization, and AI-assisted drug design, are also discussed. By consolidating\nthis fragmented literature into a single cross-scaffold structure-activity framework\nand by pinpointing where pharmacokinetic and toxicological characterization, rather than potency\noptimization, most limits clinical translation, this review provides a practical, decisionoriented\nresource for researchers designing the next generation of pyrazinone-based therapeutics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115734064519985260907100959","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:19:07Z","timestamp":1789975147000},"source":"Crossref","is-referenced-by-count":0,"title":["Pyrazinone Derivatives in Medicinal Chemistry: SAR Insights and Emerging Therapeutic Applications"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7575-3670","authenticated-orcid":true,"given":"Neetu","family":"Agrawal","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Institute of Pharmaceutical Research, GLA University, Mathura-281406, UP, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7726-7709","authenticated-orcid":true,"given":"Priya","family":"Kushwah","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Institute of Pharmaceutical Research, GLA University, Mathura-281406, UP, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7440-5228","authenticated-orcid":true,"given":"Shilpi","family":"Pathak","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Institute of Pharmaceutical Research, GLA University, Mathura-281406, UP, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115734064519985260907100959","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/258466\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115734064519985260907100959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:19:11Z","timestamp":1789975151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/258466\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115734064519985260907100959","relation":{},"ISSN":["1573-4064"],"issn-type":[{"value":"1573-4064","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}